A randomized trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria

Forty-two infants (20 males, 22 females) with classical phenylketonuria (PKU) entered a prospective, double-blind, randomized study to investigate the effects on biochemical and physiological outcomes of a phenylalanine-free infant formula containing a fat blend supplemented with the long-chain poly...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Developmental medicine and child neurology 2006-03, Vol.48 (3), p.207-212
Hauptverfasser:	Agostoni, Carlo, Harvie, Ann, McCulloch, Daphne L, Demellweek, Colin, Cockburn, Forrester, Giovannini, Marcello, Murray, Gordon, Harkness, R Angus, Riva, Enrica
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Differences Anatomy Computation Control Groups Developmental Disabilities - diagnosis Developmental Disabilities - epidemiology Double-Blind Method Evoked Potentials, Visual - physiology Fatty Acids, Unsaturated - therapeutic use Female Humans Infant Male Original Articles Outcome Measures Phenylalanine - blood Phenylketonurias - blood Phenylketonurias - drug therapy Prospective Studies Sample Size Statistical Analysis Young Children
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Forty-two infants (20 males, 22 females) with classical phenylketonuria (PKU) entered a prospective, double-blind, randomized study to investigate the effects on biochemical and physiological outcomes of a phenylalanine-free infant formula containing a fat blend supplemented with the long-chain polyunsaturated fatty acids (LC-PUFA), docosahexaenoic acid (DHA, C22:6n–3), and arachidonic acid (AA, C20:4n–6). Between entry and 20 weeks (entry and 1y) of age, median DHA levels in erythrocyte membrane phospholipids decreased by 15% (22%) in the LC-PUFA supplemented group (n=21) and by 61% (64%) in the control group (p
ISSN:	0012-1622 1469-8749
DOI:	10.1017/S0012162206000442